
Gilead Signs Generic Deals for Ebola Drug
Gilead Sciences has signed royalty-free agreements with three generic drugmakers to supply its experimental Ebola prevention drug to 127 low-income nations. The deals cover obeldesivir and aim to secure manufacturing capacity ahead of clinical trial results.
Xurve View
Insights:
Xurve View

Gilead Sciences signed royalty-free licensing deals with three generic manufacturers on Monday to supply its experimental Ebola drug to 127 low- and lower-middle-income nations. The agreements cover obeldesivir and target countries reporting cases in the active Ebola Bundibugyo outbreak. Preclinical trials show activity against Ebola-related viruses, positioning the company for pre-approval manufacturing scale-up.










